| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 81.10 mm | 81.10 mm | 81.10 mm | 81.10 mm | 81.10 mm | 81.10 mm |
| Cash burn (monthly) | 256.67 k | (no burn) | 20.67 mm | 18.51 mm | 10.76 mm | 11.08 mm |
| Cash used (since last report) | 1.30 mm | n/a | 105.05 mm | 94.05 mm | 54.67 mm | 56.30 mm |
| Cash remaining | 79.79 mm | n/a | -23.95 mm | -12.95 mm | 26.43 mm | 24.80 mm |
| Runway (months of cash) | 310.9 | n/a | -1.2 | -0.7 | 2.5 | 2.2 |
| 13F holders | Current |
|---|---|
| Total holders | 162 |
| Opened positions | 22 |
| Closed positions | 14 |
| Increased positions | 55 |
| Reduced positions | 43 |
| 13F shares | Current |
|---|---|
| Total value | 777.91 bn |
| Total shares | 69.04 mm |
| Total puts | 772.10 k |
| Total calls | 90.60 k |
| Total put/call ratio | 8.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Deep Track Capital | 5.97 mm | $78.65 bn |
| BlackRock | 5.18 mm | $68.22 bn |
| T. Rowe Price | 4.63 mm | $61.04 mm |
| FMR | 3.88 mm | $51.05 bn |
| Vanguard | 3.23 mm | $42.52 bn |
| Paradigm Biocapital Advisors | 3.20 mm | $42.11 bn |
| Redmile | 2.90 mm | $38.13 bn |
| Blue Owl Capital | 2.77 mm | $36.47 bn |
| Deutsche Bank AG - Registered Shares | 2.55 mm | $33.61 bn |
| Novartis Institutes for BioMedical Research | 2.15 mm | $40.98 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jan 25 | Bernard Coulie | Common Stock | Grant | Acquire A | No | No | 0 | 162,500 | 0.00 | 593,017 |
| 23 Jan 25 | Bernard Coulie | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 325,000 | 3.62 mm | 325,000 |
| 23 Jan 25 | Keith Lamont Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 56,650 | 0.00 | 319,258 |
| 23 Jan 25 | Keith Lamont Cummings | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 113,300 | 1.26 mm | 113,300 |
| 23 Jan 25 | Lefebvre Eric | Common Stock | Grant | Acquire A | No | No | 0 | 45,650 | 0.00 | 240,224 |
| 23 Jan 25 | Lefebvre Eric | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 91,300 | 1.02 mm | 91,300 |
| 23 Jan 25 | Hull Hans | Common Stock | Grant | Acquire A | No | No | 0 | 40,150 | 0.00 | 251,708 |
| 23 Jan 25 | Hull Hans | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 80,300 | 894.54 k | 80,300 |
| 23 Jan 25 | Mike Ouimette | Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 105,544 |
| 23 Jan 25 | Mike Ouimette | Stock Option Common Stock | Grant | Acquire A | No | No | 11.14 | 70,000 | 779.80 k | 70,000 |
